These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36405248)

  • 21. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia.
    Jurczak W; Chojnowski K; Mayer J; Krawczyk K; Jamieson BD; Tian W; Allen LF
    Br J Haematol; 2018 Nov; 183(3):479-490. PubMed ID: 30191972
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of avatrombopag in the management of severe and refractory chemotherapy-induced thrombocytopenia (CIT) in patients with solid tumors.
    Gao Y; Liu Q; Shen Y; Li Y; Shao K; Ye B; Shen Y; Zhou Y; Wu D
    Platelets; 2022 Oct; 33(7):1024-1030. PubMed ID: 35040375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Use of Thrombopoietin Receptor Agonists for Correction of Thrombocytopenia prior to Elective Procedures in Chronic Liver Diseases: Review of Current Evidence.
    Qureshi K; Patel S; Meillier A
    Int J Hepatol; 2016; 2016():1802932. PubMed ID: 27800187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.
    Al-Samkari H; Jiang D; Gernsheimer T; Liebman H; Lee S; Wojdyla M; Vredenburg M; Cuker A
    Br J Haematol; 2022 May; 197(3):359-366. PubMed ID: 35179784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled Phase 1 studies.
    Kuter DJ; Allen LF
    Br J Haematol; 2018 Nov; 183(3):466-478. PubMed ID: 30203841
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Avatrombopag for the management of thrombocytopenia in patients with chronic liver disease.
    Lozano ML
    Rev Esp Enferm Dig; 2021 Feb; 113(2):136-140. PubMed ID: 33233913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic liver disease-associated severe thrombocytopenia in Spain: Results from a retrospective study using machine learning and natural language processing.
    Calleja-Panero JL; Esteban Mur R; Jarque I; Romero-Gómez M; Group SR; García Labrador L; González Calvo J
    Gastroenterol Hepatol; 2024 Mar; 47(3):236-245. PubMed ID: 37236305
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of Thrombocytopenia in Patients with Chronic Liver Disease.
    Saab S; Brown RS
    Dig Dis Sci; 2019 Oct; 64(10):2757-2768. PubMed ID: 31011942
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag.
    Kuter DJ
    Blood Rev; 2022 May; 53():100909. PubMed ID: 34815110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Avatrombopag for the treatment of thrombocytopenia post hematopoietic stem-cell transplantation.
    Zhou M; Qi J; Gu C; Wang H; Zhang Z; Wu D; Han Y
    Ther Adv Hematol; 2022; 13():20406207221127532. PubMed ID: 36185780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Avatrombopag for the treatment of immune thrombocytopenia and thrombocytopenia of chronic liver disease.
    Cheloff AZ; Al-Samkari H
    J Blood Med; 2019; 10():313-321. PubMed ID: 31565009
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost- Effectiveness of Avatrombopag for the Treatment of Thrombocytopenia in Patients with Chronic Liver Disease.
    Mladsi D; Barnett C; Aggarwal K; Vredenburg M; Dieterich D; Kim R
    Clinicoecon Outcomes Res; 2020; 12():515-526. PubMed ID: 32982341
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of the Efficacy and Safety of Avatrombopag Combined With MSCs for the Treatment of Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplantation.
    Zhu L; Liu J; Kong P; Gao S; Wang L; Liu H; Zhang C; Gao L; Feng Y; Chen T; Gao L; Zhang X
    Front Immunol; 2022; 13():910893. PubMed ID: 35693772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Avatrombopag Effectively Maintained Platelet Counts in a Patient with Immune Thrombocytopenia Who Was Intolerant to Tyrosine Kinase Inhibitor Therapy.
    Maitland HS
    Am J Case Rep; 2021 Dec; 22():e933788. PubMed ID: 34862358
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of Avatrombopag in Patients With Thrombocytopenia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Li C; Li X; Huang F; Yang J; Wu A; Wang L; Qin D; Zou W; Wu J
    Front Pharmacol; 2019; 10():829. PubMed ID: 31402863
    [No Abstract]   [Full Text] [Related]  

  • 36. Changes in Platelet Counts and Thrombocytopenia Risk in Patients with Chronic Liver Disease with Different Etiologies Using Real-World Japanese Data.
    Yoshida M; Tateishi R; Hiroi S; Fujiwara M; Kitanishi Y; Iwasaki K; Takeshima T; Igarashi A
    Adv Ther; 2022 Feb; 39(2):992-1003. PubMed ID: 34928469
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Avatrombopag for the treatment of immune thrombocytopenia.
    Długosz-Danecka M; Zdziarska J; Jurczak W
    Expert Rev Clin Immunol; 2019 Apr; 15(4):327-339. PubMed ID: 30799645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Repeated Lusutrombopag Treatment for Thrombocytopenia in Patients with Chronic Liver Disease.
    Sano Y; Morimoto M; Kobayashi S; Ueno M; Fukushima T; Asama H; Kawano K; Nagashima S; Tanaka S; Ohkawa S; Maeda S
    Digestion; 2021; 102(4):654-662. PubMed ID: 32841939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of thrombocytopenia between patients with non-alcoholic fatty liver disease and those with hepatitis C virus-related chronic liver disease.
    Kinoshita N; Shima T; Terasaki K; Oya H; Katayama T; Matsumoto J; Mitsumoto Y; Mizuno M; Mizuno C; Hirohashi R; Sakai K; Okanoue T
    Hepatol Res; 2022 Aug; 52(8):677-686. PubMed ID: 35543116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic Review with Meta-Analysis: Efficacy and Safety of Lusutrombopag for Severe Thrombocytopenia in Patients with Chronic Liver Disease Undergoing Invasive Procedures.
    Orme ME; Bentley R; Marcella S; Peck-Radosavljevic M; Perard R; Wedemeyer H; Yoshiji H; Agarwal K; Dusheiko G
    Adv Ther; 2022 Sep; 39(9):4169-4188. PubMed ID: 35836089
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.